pembrolizumab
merck
['pembro', 'cml']
dickinson: pembrolizumab in older frail, ineligible for chemo. deliverable. no trm. does not preclude subsequent therapy.
12m survival 90%, 2y survival 83%.
#17icml 
Oncologist at Uppsala university hospital. Chair of the Swedish lymphoma group (SLG) and the Swedish Hodgkin lymphoma group.